PhoreMost Ltd
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
PhoreMost Ltd - overview
Established
2014
Location
Cambridge, -, UK
Primary Industry
Pharmaceuticals
About
Founded in 2014 and based in Cambridge, UK, PhoreMost Ltd is a biotechnology company that provides drug discovery and other pharmaceutical products and processes for cancer and other diseases. In August 2024, PhoreMost Ltd raised GBP 9. 15 million in Series B funding led by Parkwalk Advisors, with participation from Amadeus Capital Partners, Astellas Venture Management, and the Business Growth Fund. PhoreMost is a drug discovery company focused on identifying and developing therapies for difficult-to-target diseases.
Utilizing its proprietary SITESEEKER® technology, the firm employs PROTEINi® libraries to discover novel drug targets and develop strategies for targeting them. The company is advancing a pipeline that includes programs in oncology and targeted protein degradation (TPD). The company intends to use the August 2024 funding to progress the pipeline of its novel degrader programs in oncology and inflammatory diseases and support the further deployment of the GlueSEEKER™ platform.
Current Investors
Amadeus Capital Partners, Cambridge Enterprise, 5Y Capital
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.phoremost.com/
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.